-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating

HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating

MT Newswires · 01/06/2023 04:54